The C-Suite Speaks
In Vivo talks to Pfizer SVP for worldwide safety and regulatory Peter Honig on the challenges of establishing – and then maintaining – the confidence of a diverse array of constituencies in the safe, effective use of medicines for a $50 billion business.
In this supplement to our feature on the In Vivo/EBD Academy survey "Future-Proofing Human Capital In Global Life Sciences", Ramona Sequeira, President of Takeda Pharmaceutical's US Business Unit, presents her company’s strategy to anticipate and respond to a disruptive transformation of the industry payer base.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.
The threat of cyberattacks on biopharma’s extensive information assets is moving to the top of the list of business risks confronting senior C-suite management. In Vivo’s Roundtable panel of leading biopharma CISOs reviews what to do and what it will take to convince others in senior management to buy into a challenge that still remains largely below the surface.
The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Flex Health Solutions' role in the medtech space is helping other companies develop superior products for the broadest market appeal. Its ability to source ideas for medical design from other parts of its $24 billion business means it is already leveraging the Fourth Industrial Revolution, just at the point that the industry is undergoing dramatic change.
When Olympus Corp. re-entered the M&A arena after five years of "back to the basics," it was via the purchase of a company that meets every parameter of its requirements. Nacho Abia says that OR integrator Image Stream Medical should also help the Japanese multinational stay on course to meet value-based – and ambitious mid-term sales – targets.
Becton Dickinson President, Chairman and CEO Vincent Forlenza speaks to IN VIVO about the business prospects at Becton Dickinson as it integrates its major acquisition, CareFusion, and oversees a major internal group restructuring, and about his role as the current chairman of AdvaMed.
Cardiovascular Research Foundation leaders Jack Lewin, Juan Granada, and Ori Ben-Yehuda talk to IN VIVO about the state of medtech innovation and health care in the US.
Renal denervation is arguably the hottest new device technology to come along in years, with applications in a variety of chronic diseases including hypertension and diabetes, to name just two. Yet just over a decade ago, most people laughed off the concept, and they might still be laughing were it not for the efforts of a novel device development company called Coridea.
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
After emerging from the DOJ settlements, the leading pure-play orthopedics company is emphasizing – and redefining – innovation to drive growth. Zimmer CEO David Dvorak talks to IN VIVO about his company’s commitment to innovation, and how the very notion of innovation is changing.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.